Risperidone ODT Mylan

Ülke: Yeni Zelanda

Dil: İngilizce

Kaynak: Medsafe (Medicines Safety Authority)

Aktif bileşen:

Risperidone 2mg

Mevcut itibaren:

Viatris Limited

INN (International Adı):

Risperidone 2 mg

Doz:

2 mg

Farmasötik formu:

Orodispersible tablet

Kompozisyon:

Active: Risperidone 2mg Excipient: Aspartame Colloidal silicon dioxide Crospovidone Guar gum Iron oxide red Magnesium stearate Mannitol Microcrystalline cellulose Polacrilin

Reçete türü:

Prescription

Tarafından üretildi:

Mylan Laboratories Limited

Terapötik endikasyonlar:

Indicated for the treatment of schizophrenia and other psychotic disorders. These include first episode pyschoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. Risperidone also alleviates affective symptoms (such as depression, guilt feelings, anxiety) associated with schizophrenia. Risperidone also appears effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial response to treatment with this agent.

Ürün özeti:

Package - Contents - Shelf Life: Blister pack, OPA/Al/PVC-Al in cardboard carton - 14 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 28 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 56 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 84 tablets - 36 months from date of manufacture stored at or below 25°C

Yetkilendirme tarihi:

2013-12-03